000 | 01943 a2200589 4500 | ||
---|---|---|---|
005 | 20250513063309.0 | ||
264 | 0 | _c19940520 | |
008 | 199405s 0 0 eng d | ||
022 | _a1042-8194 | ||
024 | 7 |
_a10.3109/10428199309059573 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aD'Amore, F | |
245 | 0 | 0 |
_aIncidence, presenting features and prognosis of low-grade B-cell non-Hodgkin's lymphomas. Population-based data from a Danish lymphoma registry. _h[electronic resource] |
260 |
_bLeukemia & lymphoma _cDec 1993 |
||
300 |
_a69-77 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aChild |
650 | 0 | 4 |
_aChlorambucil _xtherapeutic use |
650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
650 | 0 | 4 | _aDemography |
650 | 0 | 4 |
_aDenmark _xepidemiology |
650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIncidence |
650 | 0 | 4 |
_aLymphoma, B-Cell _xdrug therapy |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNeoplasm Staging |
650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRegistries |
650 | 0 | 4 | _aSurvival Analysis |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 |
_aVincristine _xadministration & dosage |
700 | 1 | _aChristensen, B E | |
700 | 1 | _aThorling, K | |
700 | 1 | _aPedersen, M | |
700 | 1 | _aJensen, M K | |
700 | 1 | _aBoesen, A M | |
700 | 1 | _aAndersen, E | |
700 | 1 | _aJohansen, P | |
700 | 1 | _aMortensen, L S | |
773 | 0 |
_tLeukemia & lymphoma _gvol. 12 _gno. 1-2 _gp. 69-77 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428199309059573 _zAvailable from publisher's website |
999 |
_c8161258 _d8161258 |